22,493 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 22,493 shares of the company's stock, valued at approximately $740,000. GSA Capital Partners LLP owned 0.06% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of TARS. Allspring Global Investments Holdings LLC increased its stake in shares of Tarsus Pharmaceuticals by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock valued at $6,924,000 after buying an additional 29,465 shares during the period. Vanguard Group Inc. increased its stake in shares of Tarsus Pharmaceuticals by 14.5% during the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company's stock valued at $66,398,000 after buying an additional 231,131 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of Tarsus Pharmaceuticals during the first quarter valued at approximately $12,640,000. Russell Investments Group Ltd. increased its stake in shares of Tarsus Pharmaceuticals by 38,907.8% during the first quarter. Russell Investments Group Ltd. now owns 30,036 shares of the company's stock valued at $1,092,000 after buying an additional 29,959 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $28,904,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Down 0.4 %

Tarsus Pharmaceuticals stock traded down $0.20 during mid-day trading on Monday, hitting $44.63. The company had a trading volume of 817,291 shares, compared to its average volume of 732,575. The company has a current ratio of 5.42, a quick ratio of 6.99 and a debt-to-equity ratio of 0.30. The stock's 50 day moving average price is $38.11 and its two-hundred day moving average price is $32.60. Tarsus Pharmaceuticals, Inc. has a 12 month low of $15.60 and a 12 month high of $52.99. The company has a market capitalization of $1.71 billion, a PE ratio of -11.71 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $54.20.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.